Register for our S/EIS Fund

We are pleased to share that o2h discovery will be exhibiting at the XXVII EFMC International Symposium on Medicinal Chemistry held on 4-8 September at Nice, France.

The XXVll EFMC-ISMC is organized by the Société de Chimie Thérapeutique (SCT), on behalf of the European Federation for Medicinal Chemistry and Chemical Biology (EFMC) which is regularly attended by scientists including chemists, biophysicists, structural biologists among others. This year EFMC-ISMC will focus on advancements in drug development in significant therapeutic areas such as bacterial and viral infections, with a focus on current and emerging viral pandemics, but also neurodegenerative and cardiovascular diseases, rare diseases, and cancer.

EFMC-final-1

EFMC-ISMC 2022 will also feature most recent advances in new technologies such as the exploitation of RNA as drug target, artificial intelligence in drug discovery, natural products-based drug discovery, DNA encoded library applications and the development of covalent drugs, PROTACs and molecular glues. To know more please visit – https://www.efmc-ismc.org/

o2h discovery is a Contract Research Organization which has an integrated drug discovery platform operating from our state-of-the-art research centers in Ahmedabad, India and The Mill SciTech Park, Cambridge, UK.

We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development. To know more about o2h discovery, visit – https://o2h.com/discovery/chemistry/

Our drug discovery research service offerings include:
  • Integrated Drug Discovery                                                                
  • Chemistry
  • Biology
  • ADME
  • ScaleUp

We would be pleased to discuss how our service offerings can support your drug discovery programmes. Please fill out the form on the right to book a meeting with Andy Morley, Chief Scientific Officer of o2h discovery and Claudio Dagostin, Business Development Director, o2h discovery.  We look forward to seeing you at the show!

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

recent blogs

o2h-group

    Connect with us

    Comments are closed.